TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Surgical Site Injection on Pain Scores and Narcotic Use After Orthopaedic Trauma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lower extremity fracture including femoral neck, intertrochanteric, sub-trochanteric, and femoral shaft fracture~Exclusion Criteria:~* Pregnant women~* Treatment with Arthroplasty~* Patients who receive a peripheral nerve block~* Patients who receive intra-op or post-op ketamine~* Patients with concomitant TBI or MR~* Polytrauma patients~* Pathologic Fractures~* Patients who live greater than 10 miles from NYU or who will not be followed by an NYU provider~* Patients with a contraindication to any of the medications on the study list due to other medical problems such as renal or liver disease or due to allergy/intolerance~* Patients with prior extremity weakness resulting from stroke or other neurological condition~* Prior or current history of narcotic use~* Patients with advanced dementia~* NYUMC Students, Residents, Faculty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spinal Anesthesia (Type: EXPERIMENTAL): Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
- General Anesthesia (Type: ACTIVE_COMPARATOR): The control group will receive no injection into area surrounding the fracture site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weigh between 35-135 kilograms~* Low or int-1 risk MDS~* Ferritin \>1000 micrograms/liter at screening~* History of transfusion of 15 to 75 Packed Red Blood Cells (PRBC) units~* Anticipated to be transfused with at least 8 units of PRBCs annually during the study~* Women of child-bearing potential using effective methods of contraception during dosing of study treatment~Exclusion Criteria:~* More than 6 months of cumulative ICT (such as daily deferasirox (Exjade®) or deferiprone or 5×/week deferoxamine)~* More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period)~* Significant proteinuria~* History of hospitalization for congestive heart failure; other heart conditions as specified in the protocol~* Systemic diseases which would prevent study treatment~* Hepatitis B; Hepatitis C; HIV~* Liver cirrhosis~* Pregnant, or breast-feeding patients, or patients of child-bearing potential not employing an effective method of birth control~* History of drug or alcohol abuse within the 12 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): 10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
- Placebo (Type: PLACEBO_COMPARATOR): 10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Chronic hepatitis C infection (positive for anti-HCV antibody or HCV RNA at least 6 months before screening and at the time of screening; or positive for anti-HCV antibody or HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection)~* Screening laboratory result indicating HCV genotype 1 infection (HCV GT1)~* Participant must have documentation of adherence to a prior pegIFN/RBV combination therapy and meet one of the protocol definitions for treatment failure: null responder, partial responder, relapser~* No evidence of liver cirrhosis~Exclusion Criteria:~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Positive screen for drugs or alcohol~* Significant sensitivity to any drug~* Use of contraindicated medications within 2 weeks of dosing~* Abnormal laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 3-DAA/RBV (Type: EXPERIMENTAL): 3-DAA (ABT-450/r/ABT-267 \[150 mg/ 100 mg/ 25 mg once daily\] and ABT-333 \[250 mg twice daily\]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
- TPV/RBV (Type: ACTIVE_COMPARATOR): TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously \[SC\] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed severe hypertension~Exclusion Criteria:~* Inability to discontinue all prior antihypertensive medications~* Heart failure of any kind~* History of stroke, transient ischemic attack, myocardial infarction, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease~* Diabetes with poor glucose control~* Allergy to certain medications used to treat high blood pressure~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* atrial fibrillation of less than 48 hours' duration.~Exclusion Criteria:~* AF of more than 48 hours'~* hemodynamic instability~* acute onset atrial fibrillation due to acute coronary syndrome~* electrolyte disturbances~* sepsis~* fever~* hypothermia~* untreated hyperthyroidism~* use of antiarrhythmic drugs~* high embolic risk~* unclear duration of symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- electrical cardioversion (Type: EXPERIMENTAL): Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
- propafenone (Type: ACTIVE_COMPARATOR): Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ureteral Jets on Cystoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adult~* undergoing a cystoscopy or as part of their planned procedure~Exclusion Criteria:~* Chronic kidney disease~* known prior surgical removal of kidney or ureteral obstruction~* Current ureteral stent placed~* Allergy to any of the interventions

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Normal Saline (Type: ACTIVE_COMPARATOR): Infused into the bladder to allow for visualization of bladder walls and urine jets.
- Dextrose 10% (Type: EXPERIMENTAL): Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
- Phenazopyridine (Type: EXPERIMENTAL): Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
- Sodium Fluorescein (Type: EXPERIMENTAL): Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants of both genders who are in generally good health will be eligible for this study. For infants to be enrolled, the parents/legal representatives need to provide written informed consent and to be available for all study visits.~Exclusion Criteria:~* Serious, acute, or chronic illnesses are reasons for exclusion.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- MenACWY3 (Type: EXPERIMENTAL): Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
- MenACWY4 (Type: EXPERIMENTAL): All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
- Routine Vaccines (Type: PLACEBO_COMPARATOR): Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children 5-17 years of age.~2. Diagnosis of active Crohn's Disease.4. Patients with a PCDAI≥10 ≤40 (mild to moderate disease).~3. Have involvement of the colon and/or terminal ileum.~4. Disease defined as L1, L2, L3 or any of the above and may have gastric, duodenal or esophageal disease (L4a) according to the Paris classification for site of disease.~5. The CRP ≥ 0.6 mg/dL.~6. Duration of disease since diagnosis \< 3 years.~7. Negative stool culture, Clostridium Difficile Toxin from current flare.~Exclusion Criteria:~1. Duration of disease since diagnosis \> 3 years.~2. Positive stool culture or O\&P last 30 days.~3. Presence of clostridium difficile toxin in stool.~4. Azithromycin or Metronidazole allergy or known intolerance.~5. Diagnosis of IBD -U.~6. Presence of macroscopic disease involving the proximal ileum or jejunum (L4b).~7. Continuous macroscopic disease of the colon appearing as typical ulcerative colitis and Crohns diagnosed only by focality or granuloma on biopsies.~8. Presence of extraintestinal manifestations (such as arthritis, uveitis, or sclerosing cholangitis).Apthous lesions of mouth can be included.~9. Presence of fibrostenotic disease (strictures with prestenotic dilatation).~10. Presence of penetrating disease (fistulas or abscess).~11. Presence of current perianal disease defined as fistula or abscess.~12. Patients receiving concurrent corticosteroids or biologics.~13. Patients who have received steroids in the past 14 days.~14. Immune deficiency (CGD, GSD1, IL10R etc).~15. Known allergy or intolerance to any of the study medications.~16. Concurrent diseases such as hepatitis, ALT \>2 times UNL, renal failure.~17. Pregnancy.~18. Patients with known heart disease.~19. Prolonged QTc by E.C.G at baseline.~20. Patient after surgical resection.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin + Metronidazole (Type: EXPERIMENTAL): Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
- Metronidazole (Type: ACTIVE_COMPARATOR): Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Customized Medication Adherence Enhancement for Treating Adults With Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of bipolar disorder (BPD) Type I or Type II, as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)~* Demonstrated history of poor medication adherence, as determined by self-report or clinician report. In this study, self-reported treatment nonadherence will be identified with the Tablet Routines Questionnaire (TRQ). Poorly adherent individuals will be defined as those who miss 30% or more of medication within either the past week or past month (those missing 30% or more within past week will be considered to be nonadherent over the past month). Clinician-assessed nonadherence will be identified via a clinician version of the TRQ to identify nonadherence of 30% or more over the past 30 days.~* BPD of at least 2 years' duration~* Treatment with medication to stabilize mood for at least 6 months~Exclusion Criteria:~* Unable/unwilling to participate in psychiatric interviews, as based on the clinical opinion of the investigator or the treating clinician~* High risk of suicide, as seen in factors such as active suicidal ideation, recent suicide attempt, or current intent or plan~* Inability to speak English~* Individuals who have participated in Project 1, Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Customized Adherence Enhancement (CAE) (Type: EXPERIMENTAL): Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to read and understand the informed consent document; must sign the informed consent.~2. Aged 18 to 75 years old , sex is not limited~3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection~4. Availability of at least 1 g tumor sample.~5. Karnofsky functional status rating \> or equal to 70.~6. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] ), and adequate renal function (BUN and creatinine \<1.5 times IULNs)~7. Agree to Surgical indications of Heart \& lung and without the coagulation system disease~8. Negative pregnancy test for female patients of childbearing potential~9. Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration~Exclusion Criteria:~1. Inability to comply with study-related procedures~2. patient not suitable for Neurosurgery.~3. Unavailability of at least 6 doses of vaccine~4. Progression prior to vaccination as determined by the Principal Investigator~5. Patient with allergic constitution~6. Unstable or severe intercurrent medical conditions~7. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection.~8. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids.~9. any other clinical trials within 30 days pre-vaccination.~10. Female patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- gp96 group (Type: EXPERIMENTAL): autologous gp96 vaccination + basal treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local and Intravenous Dexamethasone on Post Operative Pain a After CS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All participants were scheduled for elective cesarean section under spinal anaesthesia~Exclusion Criteria:~* Women with neurological disorders~* Psychologically disturbed~* Those with uncontrolled hypertension, Diabetes Mellitus, peptic ulcer, liver cirrhosis or glaucoma~* Women with systemic infections~* Allergy to Dexamethasone~* Contraindications to spinal anaesthesia

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- IV dexamethasone (Type: ACTIVE_COMPARATOR): 40 women received 16 mg Dexamethasone IV drip.
- Local dexamethasone (Type: ACTIVE_COMPARATOR): 40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
- placebo (Type: PLACEBO_COMPARATOR): Placebo in the form of IV fluids 500 cc saline infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete